Objective To explore the therapeutic effect, safety of cetuximab plus vinorelbine and cisplatin (NP plan) on advanced non-small cell lung cancer (NSCLC) and its possible mechanisms. Methods The 58 cases of patients with advanced NSCLC firstly admitted in our hospital were selected and randomly divided into the research group (29 cases) and the control group (29 cases). Patients in the research group were treated with cetuximab plus chemotherapy of NP plan, while patients in the control group were treated only with chemotherapy of NP plan. The therapeutic effect, incidence of adverse reactions and changes of serum EGFR concentration were observed and compared between the two groups. Results The effective rate of the research group and the control group were 51.72%and 48.28%respectively. The disease control rate of the research group and the control group were 89.66%and 82.76%respectively. No significant difference was found in the effective rate and disease control rate between the two groups (P>0.05). There was also no significant difference in the 1-year survival rate and median survival time between the two groups (P>0.05). The distant metastasis rate of the research group (6.90%) was significantly lower than that of the control group (27.59%) (P<0.05). The incidence of rash in the research group was significantly higher than that of the control group (P<0.05). After treatment, The serum EGFR level of the research group was significantly lower than that of the control group (P<0.05). Conclusion Cetuximab plus NP plan was more effective and safer in the treatment of advanced NSCLC than NP plan alone. The combination treatment could reduce the tumor metastasis rate and had the adverse reactions tolerated. This might be related to the decrease of serum EGFR level.%目的：探讨西妥昔单抗联合长春瑞宾和顺铂（NP方案）治疗晚期非小细胞肺癌（NSCLC）的临床效果、安全性及其可能机制。方法选取在我院初诊的58例晚期NSCLC患者为研究对象，并将其随机分为研究组和对照组，每组各29例患者。研究组采用西妥昔单抗联合NP方案化疗，对照组仅采用NP方案化疗。治疗结束后，观察和比较两组的疗效、不良反应的发生情况及治疗前后血清表皮生长因子受体（EGFR）含量的变化。结果研究组和对照组的临床有效率分别为51.72％和48.28％，疾病控制率分别为89.66％和82.76％，差异均无统计学意义（P>0.05）；研究组的1年生存率、中位生存期与对照组相比，差异无统计学意义（P>0.05）；研究组远处转移率（6.90％）显著低于对照组（27.59％）（P<0.05）；研究组的皮疹发生率显著高于对照组（P<0.05）；治疗后，研究组的血清EGFR含量显著低于对照组（P<0.05）。结论西妥昔单抗联合NP方案治疗NSCLC的临床疗效明显优于单独用NP方案治疗，可明显降肿瘤转移的发生率，不良反应可耐受，这可能与其降低患者血清EGFR水平有关。
展开▼
